Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Stock Report

| More

Sun Pharma announces 5-Year Sustained Efficacy and Safety Results for ILUMYA® (tildrakizumab-asmn) in Patients with Moderate-to-Severe Plaque Psoriasis

Posted On: 2020-10-31 08:44:23


Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" including its subsidiaries and/or associate companies) today announced that one of its wholly owned subsidiaries presented positive, five-year Phase 3 data for ILUMYA® (tildrakizumab-asmn) from the combined reSURFACE 1 and reSURFACE 2 extension studies. Patients with moderate-to-severe plaque psoriasis who continued to receive ILUMYA through five years of continuous treatment maintained consistent and extensive skin clearance with no new safety issues reported.1 These data were presented for the first time at the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress.

"These results are important as we now have five-year data reinforcing our understanding that ILUMYA may provide patients with sustained skin clearance and a well understood safety profile that was comparable to placebo," said Richard Langley, M.D., FRCPC, professor of medicine and director of research, Department of Medicine, Dalhousie University. "ILUMYA is a valued option for patients in the treatment of moderate-to-severe plaque psoriasis, and these findings are reassuring for physicians and their patients living with this chronic disease."

In an analysis of the pooled reSURFACE 1 and reSURFACE 2 extension studies, patients received ILUMYA 100 mg or 200 mg through five years of continuous treatment. ILUMYA 100 mg is approved in the U.S., Japan and Australia, and 200 mg is additionally approved under the brand name ILUMETRI™ in Europe. In patients who were treated with ILUMYA 100 mg, clear or almost clear skin (PASI 90) was achieved by 65.9% of patients and 32.8% of patients achieved completely clear skin (PASI 100) at Week 244. The standard goal of treatment, a PASI 75 response, was achieved by 88.7% of patients at Week 244.1 The long-term analyses also showed absolute PASI <1/<3/<5 scores at Week 28 (50.8%, 85.1% and 96.4%, respectively) were sustained through Week 244 (47.7%, 78.8% and 88.7%, respectively).1 Absolute PASI scores can provide an indication of the extent of residual disease after treatment. Achievement of an absolute PASI score of <3 has been proposed as comparable to a PASI 90 response, which is equivalent to clear or almost clear skin.3

ILUMYA 100 mg was well-tolerated during the Phase 3 trials. The three adverse reactions that occurred more frequently than placebo and ≥1% in clinical trials were upper respiratory infections (14% vs. 12%), injection site reactions (3% vs. 2%) and diarrhea (2% vs. 1%). Furthermore, the analysis demonstrated similar exposure-adjusted incidence rates of malignancies throughout five years of study. A majority of malignancies were singular events with similar incidence rates as seen in the general US population.2

"These impressive results show that ILUMYA keeps working year-on-year, maintaining a high level of skin clearance and a durable safety profile regardless of baseline level of skin disease, age or background illnesses," said Abhay Gandhi, CEO, Sun Pharma, North America. "Patients living with moderate-to-severe plaque psoriasis need therapies they can use over long periods of time without loss of efficacy, and we are pleased these data show that ILUMYA is a sustainable choice for patients over the long term."

ILUMYA is approved for adults with moderate-to-severe plaque psoriasis and is being evaluated for other possible uses. See ongoing studies below for more information. Visit www.ILUMYA.com to learn more about the ILUMYA SUPPORT Lighting the Way® program that helps patients get started with treatment, understand cost and saving options, and connect with experts and others living with plaque psoriasis.

Shares of SUN PHARMACEUTICAL INDUSTRIES LTD. was last trading in BSE at Rs.465.75 as compared to the previous close of Rs. 456.75. The total number of shares traded during the day was 245758 in over 6145 trades.

The stock hit an intraday high of Rs. 468.85 and intraday low of 455.9. The net turnover during the day was Rs. 113622440.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com






Other Headlines:

Spandana Sphoorty Financial Limited raises Rs. 100 crore through NCD issue

Agra Etawah Bypass BOT Project receives Completion Certificate

Thomas Cook India launches India's first Virtual Holiday Store

Bank of Baroda files insolvency application against Kesar Terminals & Infrastructure Ltd and subsidiary

Lasa Supergenerics Ltd receives further Injunction from Hon'ble High Court, Bombay restraining its competitor from Manufacturing albendazole

Indinfravit Trust declares distribution of Rs. 2.1598

Kirloskar Electric Company Ltd has laid off balance workmen at Uni5-15

Fire incident at The Ruby Mills Ltd's Dhamni Factory

ICRA updates on ratings of Dixon Technologies (India) Ltd

Gayatri Projects Limited receives Rs. 208 crore arbitral award

Datamatics enters into a buy-back arrangement with Cignex to divest its stake

Shahlon Silk Industries has sold land to reduce debt

Prakash Pipes Limited to issue 35 lakh shares on preferential basis

V2 Retail Ltd opens 2 new retail stores in Bihar and UP

XacBank Mongolia Selects Infosys Finacle to Power its Digital Transformation

Maruti Suzuki Subscribe expands to Mumbai, Chennai, Ahmedabad and Gandhinagar

Newgen Positioned as a Visionary in Gartner Magic Quadrant for Content Services Platforms

Gillanders Arbuthnot and Company Limited enters into MoU for sale of Tengapani Tea Estate

Steel Strips Wheels Ltd receives export orders of nearly 62,000 wheels

EPL Ltd to raise Rs. 50 crore through commercial papers

Infibeam Avenues Collaborates with Bank Muscat, Oman's biggest bank, to offer high-end PG services to merchants in Oman

Wintac Ltd promoters accept discovered price of Rs. 350 for delisting offer

Äbhayam (Abhaya) Project Inaugurated

GMR Kamalanga Energy Ltd ordered to pay Rs. 1005 crore to SEPCO Electric Power Construction Corporation

Jio Platforms Limited receives subscription amount of Rs. 33,737 crore from Google

Central Bank of India Supported to install Police Station at Marine Drive

UN extends contract of Trigyn Technologies Inc for providing IT staffing support service to OICT

Jubilant Industries Limited to sell its portable liquor license to manufacture IMFL

Open Offer to acquire shares of Timex Group India Ltd at Rs. 24.26 per share

Exide Industries Limited raises stake in Exide Leclanche Energy Pvt Ltd to 80.15%

NMDC bags CSR Excellence Awards

Central Bank of India organized Road Show and distributed MASKS

NIIT Earns Two Coveted Learning Technologies 2020 awards jointly with MetLife

Suyog Telematics Limited awarded as Asia's 200 Best under A Billion 2020 by Forbes

Burgan Bank deploys iGTB's Digital Transaction Banking platform with powerful channel capabilities to power its corporate banking expansion strategy

Airtel and Vedantu empower millions of school children with affordable access to quality education on their home TV screens

Biocon Limited to acquire 26% stake in Hinduja Renewables Two Private Limited

Ircon International Ltd bags orders of Rs. 723 crore

Radio City launches the 12th Season of 'Radio City Super Singer'

Recently published data on Favipiravir as treatment for mild to moderate COVID-19 demonstrates significant improvement in time to clinical cure

ICRA reaffirms longterm rating of BEML Limited

Hester Biosciences Nepal launches a Live Thermo-tolerant PPR Vaccine

Sukhjit Starch & Chemicals Ltd's subsidiary to inaugurate Mega Food Park project on Nov 24, 2020

TCS OmniStore™ Named the POS Technology of the Year at the Retail Systems Awards 2020

Strides Pharma Global Pte. Ltd. receives USFDA approval for Prednisone Tablets

Mindtree Partners with the Nordex Group to Drive Forward the Company's Digital Transformation Journey

Vivimed Labs Limited receives product approvals for 3 ophthalmic products, 3 oral liquid suspension products

Max Estate starts construction of commercial realty project Max Square in Noida at Rs 400 crore cost, with New York Life Insurance Company as financial partner

Praj Industries Ltd signs MoU with Petroleum Ministry to facilitate setting up of CGB plants

SREI Infrastructure Finance Ltd plunges on RBI audit



Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019